GLP-1 RAs in Eating Disorders: Promising or Perilous?
In this Medscape article, writer Batya Swift Yasgur explores the role GLP-1A medications play in eating disorders and features Dr. Elizabeth Wassenaar in this discussion. In the piece, Dr. Wassenaar notes "serious concerns" about the effect these medications may have on those with disordered eating and with diagnosed and undiagnosed eating disorders.
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) continue to skyrocket in popularity as both approved and off-label treatments for weight loss. However, their widespread use raises significant concerns about their potential impact on people with eating disorders (EDs), which are prevalent worldwide. According to the World Health Organization, 14 million people globally experienced an ED in 2019. In the United States, approximately 9% of the population (28.8 million Americans) will experience an ED at some point in their lifetime.
